
(MedPage Today) — A new treatment algorithm from the European Association for the Study of Obesity (EASO) recommends opting for semaglutide (Wegovy) or tirzepatide (Zepbound) first when “substantial” weight loss is needed in a patient.
The two…
Source link : https://www.medpagetoday.com/primarycare/obesity/117800
Author :
Publish date : 2025-10-03 21:39:00
Copyright for syndicated content belongs to the linked
Source.